Cite
HARVARD Citation
Schadendorf, D. et al. (2019). Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial. Lancet oncology. 20 (5), pp. 701-710. [Online].